The quarter saw Regeneron grow its revenue by 10% year over year to just under $3.79 billion. Although non-GAAP (adjusted) ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results , with sales up 10.3% year on year to $3.79 billion. Its ...

February 4, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023 and ...

“All of this health information—their health records and the biospecimens—are coming to us de-identified,” Regeneron spokesperson Ella Campbell tells Fortune. “We have all of these data ...

The center will have exclusive rights to perform all research-related sequencing on samples collected under the collaboration, Regeneron said. Both Regeneron and Truveta will use the data to ...

Regeneron also hopes for a retinal vein occlusion ... We know the retinal community very well. But we didn’t have all the tools necessary to optimize Eylea HD.” Roche's Vabysmo will rise ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 10 trades.

Regeneron collaborates with Truveta to expand ... up to ten million additional de-identified patient volunteers, all with linked electronic health records (EHRs). This novel resource is designed ...

Regeneron pledged $119.5m while Illumina is ... of the party’s pledge to fix the National Health Service (NHS). The All of Us Research Program (AOR) from the National Institutes of Health ...